Compensatory roles of Protein Related to DAN and Cerberus (PRDC) decrease in pulmonary arterial hypertension

Bone morphogenetic protein (BMP) signaling is commonly suppressed in patients with pulmonary arterial hypertension (PAH), but the compensatory mechanism of BMP signaling suppression is incompletely elucidated.This study aimed to investigate the role of PRDC, an antagonist of BMPs, in PAH and the underlying mechanism.Human lungs were collected and rat PAH was induced (monocrotaline, 60 mg/kg).BMP cascade and PRDC were detected in lungs and distal pulmonary artery smooth muscle cells (dPASMCs).In vitro cell experiments and in vivo supplementation of PRDC in hypertensive rats were subsequently performed.PRDC and BMP cascade all decreased in human and rat hypertensive lungs.Cell experiments confirmed that BMP2/4 inhibited dPASMCs proliferation by increasing cell cycle inhibitors (p21, p27), prevented dPASMCs migration by down-regulating MMP2/9 and up-regulating TIMP1/2 expression, and promoted dPASMCs apoptosis by up-regulating Bax, caspase3/9 and down-regulating Bcl-2 expression, as well as enhancing caspase3/7 activity, while, PRDC reversed the effects of BMP2/4 on dPASMCs proliferation, migration and apoptosis.In vivo trial found that PRDC supplementation deteriorated rat PAH in terms of pulmonary hemodynamics, vasculopathies and right ventricle hypertrophy.Taken together, compensatory decrease of PRDC in hypertensive lungs theoretically slow down the natural course of PAH, suggesting its therapeutic potential in PAH.